nicotine indications/contra

Stem definitionDrug idCAS RN
1920 54-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicotine
  • L-Nicotine
  • (S)-Nicotine
  • (-)-Nicotine
  • nicotine bitartrate anhydrous
  • nicotine polacrilex
Items used to aid in ending a TOBACCO habit.
  • Molecular weight: 162.24
  • Formula: C10H14N2
  • CLOGP: 0.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 16.13
  • ALOGS: -0.24
  • ROTB: 1

Drug dosage:

DoseUnitRoute
30 mg Chewing gum
60 mg Inhal
30 mg N
30 mg SL
14 mg TD

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 1991 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 1113.58 35.79 146 2296 105 3383312
Drug dependence 946.17 35.79 188 2254 4188 3379229
Incorrect drug administration duration 772.51 35.79 152 2290 3189 3380228
Overdose 682.68 35.79 217 2225 33761 3349656
Foetal exposure during pregnancy 609.36 35.79 167 2275 15384 3368033
Intentional product misuse 560.93 35.79 150 2292 12551 3370866
Accidental overdose 526.34 35.79 127 2315 6991 3376426
Drug withdrawal syndrome neonatal 504.80 35.79 100 2342 2150 3381267
Toxicity to various agents 271.06 35.79 121 2321 46933 3336484
Drug ineffective 270.53 35.79 162 2280 115928 3267489
Dependence 264.30 35.79 48 2394 627 3382790
Maternal exposure during breast feeding 263.28 35.79 53 2389 1227 3382190
Product adhesion issue 254.95 35.79 54 2388 1616 3381801
Application site erythema 237.96 35.79 53 2389 2014 3381403
Premature baby 193.42 35.79 58 2384 7195 3376222
Nausea 183.98 35.79 133 2309 129512 3253905
Application site pruritus 182.07 35.79 40 2402 1422 3381995
Product quality issue 176.91 35.79 76 2366 26659 3356758
Myocardial stunning 155.95 35.79 21 2421 22 3383395
Palpitations 145.32 35.79 60 2382 19023 3364394
Low birth weight baby 139.47 35.79 33 2409 1637 3381780
Application site rash 125.09 35.79 28 2414 1083 3382334
Drug abuse 124.01 35.79 53 2389 18277 3365140
Drug abuser 123.69 35.79 33 2409 2670 3380747
Maternal drugs affecting foetus 112.82 35.79 33 2409 3738 3379679
Drug screen positive 109.75 35.79 28 2414 1900 3381517
Drug administration error 108.12 35.79 36 2406 6240 3377177
Exposure during pregnancy 106.27 35.79 54 2388 27509 3355908
Completed suicide 105.74 35.79 56 2386 31058 3352359
Anxiety 100.97 35.79 59 2383 39570 3343847

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N07BA01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in nicotine dependence
CHEBI has role CHEBI:59163 biomarker
CHEBI has role CHEBI:50846 immunomodulator
CHEBI has role CHEBI:49110 peripheral nervous system drug
CHEBI has role CHEBI:35471 psychotropic drug
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:47958 nicotinic acetylcholine receptor agonist
CHEBI has role CHEBI:22917 phytogenic insecticide
FDA EPC N0000175706 Cholinergic Nicotinic Agonist
FDA Chemical/Ingredient N0000006496 Nicotine
MeSH PA D001337 Autonomic Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018679 Cholinergic Agonists
MeSH PA D005731 Ganglionic Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018722 Nicotinic Agonists
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Nicotine dependence indication 56294008 DOID:0050742
Smoking cessation assistance indication 384742004
Pellagra indication 418186002 DOID:8457
Niacin deficiency indication 418279001 DOID:8457
Nicotine Withdrawal Symptoms indication
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Temporomandibular joint disorder contraindication 41888000
Low blood pressure contraindication 45007003
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Prinzmetal angina contraindication 87343002
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Pheochromocytoma contraindication 302835009
Acute coronary syndrome contraindication 394659003
Pharyngitis contraindication 405737000 DOID:2275
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000
Life-Threatening Cardiac Arrhythmias contraindication
Hyperlipidemia off-label use 55822004 DOID:1168

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.05 Basic
pKa2 3.14 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
14MG/24HR NICODERM CQ SANOFI AVENTIS US N020165 Aug. 2, 1996 OTC FILM, EXTENDED RELEASE TRANSDERMAL 8999379 Feb. 13, 2020 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
21MG/24HR NICODERM CQ SANOFI AVENTIS US N020165 Aug. 2, 1996 OTC FILM, EXTENDED RELEASE TRANSDERMAL 8999379 Feb. 13, 2020 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
7MG/24HR NICODERM CQ SANOFI AVENTIS US N020165 Aug. 2, 1996 OTC FILM, EXTENDED RELEASE TRANSDERMAL 8999379 Feb. 13, 2020 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel AGONIST Ki 8.56 WOMBAT-PK CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel Ki 5.83 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 4.15 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.68 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 5.95 WOMBAT-PK
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 7.85 WOMBAT-PK
Cytochrome P450 2A6 Enzyme IC50 5.36 WOMBAT-PK
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 7.40 WOMBAT-PK
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 5.39 WOMBAT-PK
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.80 IUPHAR
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 7.64 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel IC50 7.35 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel IC50 7.07 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 9.03 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel IC50 8.15 CHEMBL
Neuronal acetylcholine receptor Ion channel Kd 11 CHEMBL
Neuronal acetylcholine receptor subunit alpha-9 Ion channel Kd 8.30 CHEMBL
Neuronal acetylcholine receptor subunit beta-4 Ion channel Ki 7.14 CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel Ki 7.92 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 6.70 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Nicotinic acetylcholine receptor alpha 5 subunit Ion channel Ki 5.61 CHEMBL
Acetylcholine receptor subunit delta Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Kd 9.40 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.89 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.61 CHEMBL
Acetylcholine receptor Ion channel Ki 5.20 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel Ki 7.33 CHEMBL
Acetylcholine receptor subunit beta-like 2 Ion channel Ki 5.57 CHEMBL
Muscarinic acetylcholine receptor GPCR IC50 4.55 CHEMBL
Lycopene cyclase Enzyme IC50 5.32 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.64 CHEMBL
Soluble acetylcholine receptor Unclassified Ki 7.52 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 8.72 CHEMBL
Acetylcholine-binding protein Unclassified Ki 7.20 CHEMBL
Potassium voltage-gated channel subfamily D member 3 Unclassified BLOCKER IC50 7.40 IUPHAR

External reference:

scroll-->
IDSource
CHEBI:17688 CHEBI
DB00184 DRUGBANK_ID
2585 IUPHAR_LIGAND_ID
4020286 VUID
N0000148163 NUI
C0028040 UMLSCUI
D03365 KEGG_DRUG
CHEMBL3 ChEMBL_ID
6M3C89ZY6R UNII
65-31-6 SECONDARY_CAS_RN
4020286 VANDF
11529 MMSL
7407 RXNORM
323283001 SNOMEDCT_US
68540007 SNOMEDCT_US
5173 MMSL
d00316 MMSL
373462006 SNOMEDCT_US
N0000148163 NDFRT
N0000006496 NDFRT
001770 NDDF
CHEMBL1201536 ChEMBL_ID
D009538 MESH_DESCRIPTOR_UI
D061485 MESH_DESCRIPTOR_UI
89594 PUBCHEM_CID
NCT PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5400 INHALANT 4 mg RESPIRATORY (INHALATION) NDA 14 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 15 sections
Meijer NICOTINE TRANSDERMAL SYSTEM HUMAN OTC DRUG LABEL 1 0067-6011 PATCH, EXTENDED RELEASE 7 mg TOPICAL NDA 15 sections
Meijer NICOTINE TRANSDERMAL SYSTEM HUMAN OTC DRUG LABEL 1 0067-6012 PATCH, EXTENDED RELEASE 21 mg TOPICAL NDA 15 sections
Meijer NICOTINE TRANSDERMAL SYSTEM HUMAN OTC DRUG LABEL 1 0067-6013 PATCH, EXTENDED RELEASE 21 mg TOPICAL NDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0029 GUM, CHEWING 2 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0053 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0170 GUM, CHEWING 4 mg ORAL ANDA 10 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-0206 GUM, CHEWING 2 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0344 LOZENGE 2 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0422 GUM, CHEWING 4 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0456 GUM, CHEWING 2 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0532 GUM, CHEWING 4 mg ORAL ANDA 10 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0704 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0713 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0734 LOZENGE 2 mg ORAL ANDA 11 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0749 GUM, CHEWING 4 mg ORAL ANDA 10 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0761 GUM, CHEWING 2 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0854 GUM, CHEWING 4 mg ORAL ANDA 10 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-0873 LOZENGE 4 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0957 LOZENGE 4 mg ORAL ANDA 11 sections
Nicotine HUMAN OTC DRUG LABEL 1 0113-2365 GUM, CHEWING 2 mg ORAL ANDA 10 sections
Nicotine Polacrilex HUMAN OTC DRUG LABEL 1 0113-2442 GUM, CHEWING 4 mg ORAL ANDA 9 sections
Tru Relief Nicotine HUMAN OTC DRUG LABEL 1 0113-6000 LOZENGE 2 mg ORAL ANDA 15 sections
Tru Relief Nicotine HUMAN OTC DRUG LABEL 1 0113-6001 LOZENGE 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7170 GUM, CHEWING 4 mg ORAL ANDA 10 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7456 GUM, CHEWING 2 mg ORAL ANDA 10 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7532 GUM, CHEWING 4 mg ORAL ANDA 10 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-8442 GUM, CHEWING 4 mg ORAL ANDA 10 sections